BACKGROUND: The so-called thorough QT/QTc (TQT) studies required for every new pharmaceutical compound are negative if upper single-sided 95% confidence interval (CI) of placebo and baseline corrected QTc prolongation is <10 ms. This tight requirement has many methodological implications. If the investigated drug has a fast action and ECGs cannot be obtained at stable heart rates, QT/RR hysteresis correction is needed. METHODS: This was used in a TQT study of gadobutrol. The TQT study was a randomized double-blind five-times crossover study of three doses of gadobutrol (0.1, 0.3, and 0.5 mmol/kg) that was placebo and positive effect controlled (moxifloxacin 400 mg). The study enrolled 50 healthy subjects with data of all periods. QT/RR hysteresis was assessed from prestudy exercise test ECGs. Among others, comparisons were made between population heart rate correction without hysteresis considerations and combined population heart rate and hysteresis correction. RESULTS: The highest heart rate increase (placebo and baseline controlled) of 13.1 beats per minute (90% CI 9.9-16.4) occurred 1 minute after the administration of the highest dose of gadobutrol. Without hysteresis consideration, the highest DeltaDeltaQTc were 9.91 ms (90% CI 8.01-11.81) while with hysteresis correction, these values were 7.62 ms (90% CI 6.37-8.87), thus turning a marginally positive TQT study into a negative finding. CONCLUSION: Hence, omitting hysteresis correction from episodes of fast heart rate changes may lead to incorrect conclusions. Despite substantial rate acceleration, accurate hysteresis correction confirms that gadobutrol does not have any effects on cardiac repolarization that would be within the limits of regulatory relevance.
RCT Entities:
BACKGROUND: The so-called thorough QT/QTc (TQT) studies required for every new pharmaceutical compound are negative if upper single-sided 95% confidence interval (CI) of placebo and baseline corrected QTc prolongation is <10 ms. This tight requirement has many methodological implications. If the investigated drug has a fast action and ECGs cannot be obtained at stable heart rates, QT/RR hysteresis correction is needed. METHODS: This was used in a TQT study of gadobutrol. The TQT study was a randomized double-blind five-times crossover study of three doses of gadobutrol (0.1, 0.3, and 0.5 mmol/kg) that was placebo and positive effect controlled (moxifloxacin 400 mg). The study enrolled 50 healthy subjects with data of all periods. QT/RR hysteresis was assessed from prestudy exercise test ECGs. Among others, comparisons were made between population heart rate correction without hysteresis considerations and combined population heart rate and hysteresis correction. RESULTS: The highest heart rate increase (placebo and baseline controlled) of 13.1 beats per minute (90% CI 9.9-16.4) occurred 1 minute after the administration of the highest dose of gadobutrol. Without hysteresis consideration, the highest DeltaDeltaQTc were 9.91 ms (90% CI 8.01-11.81) while with hysteresis correction, these values were 7.62 ms (90% CI 6.37-8.87), thus turning a marginally positive TQT study into a negative finding. CONCLUSION: Hence, omitting hysteresis correction from episodes of fast heart rate changes may lead to incorrect conclusions. Despite substantial rate acceleration, accurate hysteresis correction confirms that gadobutrol does not have any effects on cardiac repolarization that would be within the limits of regulatory relevance.
Authors: Robert R Fenichel; Marek Malik; Charles Antzelevitch; Michael Sanguinetti; Dan M Roden; Silvia G Priori; Jeremy N Ruskin; Raymond J Lipicky; Louis R Cantilena Journal: J Cardiovasc Electrophysiol Date: 2004-04
Authors: Jörn O Balzer; Christian Loewe; Kirsten Davis; Mathias Goyen; Tim Leiner; James F M Meaney; Christiane Pöckler-Schöniger; Gernot Schulte-Altedorneburg; Bernd Tombach; Rolf Vosshenrich; Robin Wegener Journal: Eur Radiol Date: 2002-12-03 Impact factor: 5.315
Authors: M Malik; J-O Andreas; K Hnatkova; J Hoeckendorff; W Cawello; M Middle; R Horstmann; M Braun Journal: Clin Pharmacol Ther Date: 2008-07-23 Impact factor: 6.875
Authors: Jimmi Nielsen; Claus Graff; Jørgen K Kanters; Egon Toft; David Taylor; Jonathan M Meyer Journal: CNS Drugs Date: 2011-06-01 Impact factor: 5.749
Authors: Eathar Razak; Marie Buncová; Vladimir Shusterman; Bruce Winter; Win-Kuang Shen; Michael J Ackerman; Theresa Donovan; Rachel Lampert; Jan Němec Journal: Ann Noninvasive Electrocardiol Date: 2011-04 Impact factor: 1.468
Authors: Mathias Baumert; Alberto Porta; Marc A Vos; Marek Malik; Jean-Philippe Couderc; Pablo Laguna; Gianfranco Piccirillo; Godfrey L Smith; Larisa G Tereshchenko; Paul G A Volders Journal: Europace Date: 2016-01-27 Impact factor: 5.214
Authors: Robert L Lux; Christopher Todd Sower; Nancy Allen; Susan P Etheridge; Martin Tristani-Firouzi; Elizabeth V Saarel Journal: PLoS One Date: 2014-01-15 Impact factor: 3.240